Last reviewed · How we verify
Placebo for Ustekinumab
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in Phase 3 clinical trial of ustekinumab (active comparator).
At a glance
| Generic name | Placebo for Ustekinumab |
|---|---|
| Sponsor | Janssen Scientific Affairs, LLC |
| Modality | Biologic |
| Phase | Phase 3 |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to natural disease progression, regression to the mean, or the placebo effect (psychological/expectation-based response). In this context, it serves as the control arm in a Phase 3 trial of ustekinumab.
Approved indications
- Control arm in Phase 3 clinical trial of ustekinumab (active comparator)
Common side effects
Key clinical trials
- A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
- LFMT vs Placebo in New Biologic Start for Ulcerative Colitis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant (PHASE2)
- A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (PHASE3)
- Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease (PHASE3)
- A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for Ustekinumab CI brief — competitive landscape report
- Placebo for Ustekinumab updates RSS · CI watch RSS
- Janssen Scientific Affairs, LLC portfolio CI